Connect Biopharma shares are trading higher after the company announced preliminary topline data from its global Phase 2 study evaluating rademikibart. Results included Rademikibart reducing rate of treatment failure, rate of moderate to severe COPD exacerbations and reduced the rate of new emergency departments and hospital admissions.